Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation

Journal of Gastroenterology

Volumn 44, Issue 6, 2009, Pages 635-642

  Ju, Min Jie ^a   Qiu, Shuang Jian ^a   Fan, Jia ^a   Zhou, Jian ^a   Gao, Qiang ^a   Cai, Ming Yan ^a   Li, Yi Wei ^a   Tang, Zhao You ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

GGT ALT; Hepatocellular carcinoma; Preoperative; Prognosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME;

ALANINE TRANSAMINASE; CARCINOMA, HEPATOCELLULAR; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; ROC CURVE; SURVIVAL ANALYSIS;

EID: 67449085798     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0050-x     Document Type: Article

References (36)

1. Lok AS. Chronic hepatitis B. N Engl J Med. 2002;346:1682-3.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-17.
3. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10-24.
4. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586-93.
5. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007;25:319-25.
6. Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer. 1997;79:688-94.
7. Nagasue N, Kohno H, Tachibana M, Yamanoi A, Ohmori H, El-Assal ON. Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis. Ann Surg. 1999;229:84-90.
8. Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, et al. Experience of 1,000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer. 2001;91:1479-86.
9. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: Prospective cohort study. BMJ. 2004;328:983-8.
10. Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2004;19:314-8.
11. Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer. 1999;86:589-95.
12. Tarao K, Rino Y, Takemiya S, Ohkawa S, Sugimasa Y, Miyakawa K, et al. Serum alanine aminotransferase levels and survival after hepatectomy in patients with hepatocellular carcinoma and hepatitis C virus-associated liver cirrhosis. Cancer Sci. 2003;94:1083-90.
13. Yao D, Jiang D, Huang Z, Lu J, Tao Q, Yu Z, et al. Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer. 2000;88:761-9.
14. Cheung YS, Chan HL, Wong J, Lee KF, Poon TC, Wong N, et al. Elevated perioperative transaminase level predicts intrahepatic recurrence in hepatitis B-related hepatocellular carcinoma after curative hepatectomy. Asian J Surg. 2008;31:41-9.
15. Fuke H, Sugimoto K, Shiraki K, Tanaka J, Beppu T, Yoneda K, et al. Predictive factors for distant recurrence of HCV-related hepatocellular carcinoma after radiofrequency ablation combined with chemoembolization. Aliment Pharmacol Ther. 2008;27:1253-60.
16. Tung-Ping Poon R, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500-7.
17. Chen CH, Huang GT, Yang PM, Chen PJ, Lai MY, Chen DS, et al. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur J Cancer. 2006;42:2524-9.
18. Sato A, Kato Y, Nakata K, Nakao K, Daikoku M, Ishii N, et al. Relationship between sustained elevation of serum alanine aminotransferase and progression from cirrhosis to hepatocellular carcinoma: Comparison in patients with hepatitis B virus- and hepatitis C virus-associated cirrhosis. J Gastroenterol Hepatol. 1996;11:944-8.
19. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: A guide for clinicians. CMAJ. 2005;172:367-79.
20. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Influence of stable, long-term treatment with phenobarbital on the activity of serum alanine aminotransferase and gamma-glutamyltransferase. Br J Biomed Sci. 2008;65:132-5.
21. Ebeling F, Lappalainen M, Vuoristo M, Nuutinen H, Leino R, Karvonen AL, et al. Factors predicting interferon treatment response in patients with chronic hepatitis c: Late viral clearance does not preclude a sustained response. Am J Gastroenterol. 2001;96:1237-42.
22. Mihm S, Monazahian M, Grethe S, Fechner C, Ramadori G, Thomssen R. Ratio of serum gamma-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-alpha in chronic HCV infection. J Med Virol. 1999;58:227-34.
23. Tarantino G, Sorrentino P, Conca P, Perrella A, Ragucci P, Perrella O. Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study. Liver Int. 2003;23:413-9.
24. Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007;47:684-90.
25. Yang XR, Xu Y, Shi GM, Fan J, Zhou J, Ji Y, et al. Cytokeratin 10 and cytokeratin 19: Predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res. 2008;14:3850-9.
26. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26:2707-16.
27. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis. 1999;19:329-38.
28. Edmondson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
29. Nagasue N, Kohno H, Chang YC, Taniura H, Yamanoi A, Uchida M, et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg. 1993;217:375-84.
30. Lorenzo CS, Limm WM, Lurie F, Wong LL. Factors affecting outcome in liver resection. HPB (Oxford). 2005;7:226-30.
31. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698-711.
32. Rajput AB, Turbin DA, Cheang MC, Voduc DK, Leung S, Gelmon KA, et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: A study of 4,444 cases. Breast Cancer Res Treat. 2008;107:249-57.
33. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995-2004.
34. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: Significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004;112:44-50.
35. Yao DF, Dong ZZ, Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2007;6:241-7.
36. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: Both or neither? Am J Gastroenterol. 2006;101:524-32.